- Home
- DATS vs CNSP Comparison
DATS vs CNSP Comparison
Compare DATS & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- CNSP
- Stock Information
- Founded
- DATS 2014
- CNSP 2017
- Country
- DATS United States
- CNSP United States
- Employees
- DATS N/A
- CNSP N/A
- Industry
- DATS Computer Software: Prepackaged Software
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- CNSP Health Care
- Exchange
- DATS Nasdaq
- CNSP Nasdaq
- Market Cap
- DATS 5.2M
- CNSP 5.4M
- IPO Year
- DATS 2021
- CNSP 2019
- Fundamental
- Price
- DATS $1.74
- CNSP $0.11
- Analyst Decision
- DATS
- CNSP Strong Buy
- Analyst Count
- DATS 0
- CNSP 1
- Target Price
- DATS N/A
- CNSP $0.50
- AVG Volume (30 Days)
- DATS 392.8K
- CNSP 4.4M
- Earning Date
- DATS 11-14-2024
- CNSP 11-15-2024
- Dividend Yield
- DATS N/A
- CNSP N/A
- EPS Growth
- DATS N/A
- CNSP N/A
- EPS
- DATS N/A
- CNSP N/A
- Revenue
- DATS $515.00
- CNSP N/A
- Revenue This Year
- DATS N/A
- CNSP N/A
- Revenue Next Year
- DATS N/A
- CNSP N/A
- P/E Ratio
- DATS N/A
- CNSP N/A
- Revenue Growth
- DATS N/A
- CNSP N/A
- 52 Week Low
- DATS $1.01
- CNSP $0.10
- 52 Week High
- DATS $4.13
- CNSP $70.00
- Technical
- Relative Strength Index (RSI)
- DATS 47.83
- CNSP 45.26
- Support Level
- DATS $1.61
- CNSP $0.10
- Resistance Level
- DATS $1.82
- CNSP $0.12
- Average True Range (ATR)
- DATS 0.16
- CNSP 0.01
- MACD
- DATS -0.03
- CNSP 0.00
- Stochastic Oscillator
- DATS 23.21
- CNSP 41.38
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts, even after they are sent.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.